Feasibility of Oral Topotecan in Previously Untreated Patients with Small-Cell Lung Cancer Ineligible for Standard Therapy

Publisher： Karger

E-ISSN： 1423-0232|61|1|42-46

ISSN： 0030-2414

Source： Oncology, Vol.61, Iss.1, 2001-09, pp. : 42-46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

Topotecan (Hycamtin®) in the Therapy of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Status of Topotecan in Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Feasibility of Oral Topotecan Plus Intravenous Paclitaxel in Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 30-34

Karger

Access to resources Recommend Favorite

Topotecan in the First-Line Treatment of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 13-17

Karger

Access to resources Recommend Favorite